Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385963 | 0.90 | MTNR1B (0.47) | MTNR1BMDM2PTPN1MDM4TP53 | |
| SCHEMBL25385958 | 0.90 | MTNR1B (0.47) | MTNR1BMDM2PTPN1MDM4TP53 | |
| SCHEMBL29363204 | 0.82 | MDM2 (0.44) | MDM2PTPN1MDM4TP53BACE1 | |
| SCHEMBL21175068 | 0.80 | MDM2 (0.52) | MDM2PTPN1MDM4TP53BACE1 | |
| SCHEMBL21175067 | 0.80 | MDM2 (0.52) | MDM2PTPN1MDM4TP53BACE1 | |
| SCHEMBL10078351 | 0.79 | MDM2 (0.48) | MDM2PTPN1MDM4TP53 | |
| SCHEMBL16093056 | 0.79 | MDM2 (0.48) | MDM2PTPN1MDM4TP53 | |
| SCHEMBL14436881 | 0.79 | MDM2 (0.47) | MDM2MDM4TP53 | |
| SCHEMBL29358858 | 0.79 | TLR2 (0.46) | MDM2PTPN1MDM4TP53 | |
| SCHEMBL27728772 | 0.78 | MDM4 (0.49) | MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2025-05-29 | — | — | US | disclosed |
| EP-4490142-A2 | PCNA INHIBITORS AND USES THEREOF | City of Hope (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | PCNA, MKI67, PCLAF | MTNR1B 4532/4885MDM2 77/4885PTPN1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.